Pharmacokinetics and Dialytic Clearance of Isavuconazole during In Vitro and In Vivo Continuous Renal Replacement Therapy
- 1 December 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (12)
- https://doi.org/10.1128/aac.01085-19
Abstract
The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid-organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated.Keywords
This publication has 25 references indexed in Scilit:
- Breakthrough Fungal Infections in Patients With Leukemia Receiving IsavuconazoleClinical Infectious Diseases, 2018
- Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care NetworkOpen Forum Infectious Diseases, 2018
- Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical TrialsAntimicrobial Agents and Chemotherapy, 2018
- Characterization of butyrylcholinesterase in bovine serumChemico-Biological Interactions, 2017
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2016
- A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokineticsCritical Care, 2015
- Antifungal Prophylaxis in Lung Transplantation—A World-wide SurveyAmerican Journal of Transplantation, 2011
- Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement TherapyClinical Pharmacokinetics, 2007
- How to Calculate Clearance of Highly Protein-Bound Drugs during Continuous Venovenous Hemofiltration Demonstrated with FlucloxacillinKidney and Blood Pressure Research, 2003
- Pharmacokinetics of Ceftriaxone in Patients Undergoing Continuous Veno-Venous HemofiltrationThe Journal of Clinical Pharmacology, 1996